A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

被引：0
|
作者：
Amy Y. Wang
Howard Weiner
Margaret Green
Hua Chang
Noreen Fulton
Richard A. Larson
Olatoyosi Odenike
Andrew S. Artz
Michael R. Bishop
Lucy A. Godley
Michael J. Thirman
Satyajit Kosuri
Jane E. Churpek
Emily Curran
Kristen Pettit
Wendy Stock
Hongtao Liu
机构：
[1] University of Chicago Medicine,Internal Medicine/Pediatric Residency Program
[2] University of Chicago Medicine,Department of Medicine, Section of Hematology/Oncology
[3] Karyopharm Therapeutics Inc,Department of Medicine, Section of Hematology/Oncology
[4] University of Michigan Medicine,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
AML; Selinexor; Induction chemotherapy; XPO1/CRM1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Idarubicin high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia.
    Eisen, T
    Powles, R
    Singhal, S
    Middleton, G
    Treleaven, J
    Mehta, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 253 - 253
  • [22] A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia
    Sweet, Kendra L.
    Komrokji, Rami S.
    Padron, Eric
    Cubitt, Christopher L.
    Khavarian, Leyla
    List, Alan F.
    Sallman, David
    Sullivan, Daniel
    Chavez, Julio C.
    Shah, Bijal D.
    Lancet, Jeffrey E.
    BLOOD, 2016, 128 (22)
  • [23] Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study
    Braess, Jan
    Amler, Susanne
    Kreuzer, Karl-Anton
    Spiekermann, Karsten
    Lindemann, Hans Walter
    Lengfelder, Eva
    Graeven, Ullrich
    Staib, Peter
    Ludwig, Wolf-Dieter
    Biersack, Harald
    Ko, Yon-Dschun
    Uppenkamp, Michael J.
    De Wit, Maike
    Korsten, Stefan
    Peceny, Rudolf
    Gaska, Tobias
    Schiel, Xaver
    Behringer, Dirk M.
    Kiehl, Michael G.
    Zinngrebe, Bettina
    Meckenstock, Gerald
    Roemer, Eva
    Medgenberg, Dirk
    Spaeth-Schwalbe, Ernst
    Massenkeil, Gero
    Hindahl, Heidrun
    Schwerdtfeger, Rainer
    Trenn, Guido
    Sauerland, Cristina
    Koch, Raphael
    Lablans, Martin
    Faldum, Andreas
    Goerlich, Dennis
    Bohlander, Stefan K.
    Schneider, Stephanie
    Dufour, Annika
    Buske, Christian
    Fiegl, Michael
    Subklewe, Marion
    Braess, Birgit
    Unterhalt, Michael
    Baumgartner, Anja
    Woermann, Bernhard
    Beelen, Dietrich
    Hiddemann, Wolfgang
    LEUKEMIA, 2018, 32 (12) : 2558 - 2571
  • [24] Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group study 2951
    Wells, RJ
    Adams, MT
    Alonzo, TA
    Arceci, RJ
    Buckley, J
    Buxton, AB
    Dusenbery, K
    Gamis, A
    Masterson, M
    Vik, T
    Warkentin, P
    Whitlock, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) : 2940 - 2947
  • [25] Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia
    Lei, Meiqing
    Liu, Limin
    Wang, Zhiming
    Wu, Depei
    INDIAN JOURNAL OF CANCER, 2019, 56 (02) : 167 - 172
  • [26] Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia.
    Larson, Melissa L.
    Burhani, Sakina
    Gallas, Kirstin
    Katz, Deborah Ann
    Hoyt, Maura
    Venugopal, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Phase I Dose-Finding Study of Eltrombopag Following High Dose Cytarabine and Mitoxantrone Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Swaminathan, Mahesh
    Przespolewski, Amanda
    Griffiths, Elizabeth A.
    Thompson, James E.
    Elshoury, Amro
    Walinski, Wendy
    Wang, Eunice S.
    BLOOD, 2021, 138
  • [28] IDARUBICIN, HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTION IN THERAPY-RELATED ACUTE MYELOID-LEUKEMIA
    PHILPOTT, N
    MEHTA, J
    TRELEAVEN, J
    POWLES, R
    LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 127 - 130
  • [29] A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia
    Christian, Sonia
    Arain, Saad
    Patel, Pritesh
    Khan, Irum
    Calip, Gregory S.
    Agrawal, Vaibhav
    Sweiss, Karen
    Griffin, Shawn
    Cahill, Kirk
    Konig, Heiko
    Esen, Aysenur
    Shergill, Ardaman
    Odenike, Olatoyosi
    Stock, Wendy
    Quigley, John G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (08) : 937 - 943
  • [30] INDUCTION THERAPY WITH HIGH-DOSE CYTARABINE AND ANTHRACYCLINES IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
    Gil, Perez Angela
    Vazquez, Ramo Alejandro
    De Rojas, de Pablo Teresa
    Torralba, Gomez de Suso Miguel
    Nuevo, Lopez Irene
    Subira, Perez Dolores
    Merchan, Munoz Beatriz
    Perez, Ortega Alba
    De Miguel, Llorente Dunia
    HAEMATOLOGICA, 2020, 105 : 384 - 385
12345